Novartis To Continue To Face Revenue Challenges In 2017
Pharma & Healthcare / Switzerland / Thu 20 Jul, 2017
While positive results in Novartis' Alcon and growing sales of new products Cosentyx and Entresto will boost investor confidence in the Swiss drugmaker, generic competition to Novartis' blockbuster Gleevec and pricing pressures on generic medicines in the US will continue to hurt company revenues in 2017. The impact of generic competition on sales